CAD
MCID: HYP724
MIFTS: 72

Hyperlipoproteinemia, Type Iii (CAD)

Categories: Blood diseases, Endocrine diseases, Genetic diseases, Liver diseases, Metabolic diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Hyperlipoproteinemia, Type Iii

MalaCards integrated aliases for Hyperlipoproteinemia, Type Iii:

Name: Hyperlipoproteinemia, Type Iii 56 36
Coronary Artery Disease 73 36 29 54 6 42 62 17 71
Hyperlipoproteinemia Type Iii 12 74 52 73 54 43 15 71
Broad-Betalipoproteinemia 56 52 73 71
Familial Type 3 Hyperlipoproteinemia 12 29 6
Floating-Betalipoproteinemia 56 73 71
Hyperlipemia with Familial Hypercholesterolemic Xanthomatosis 56 73
Familial Hypercholesterolemia with Hyperlipemia 56 73
Familial Hyperbeta- and Prebetalipoproteinemia 56 73
Coronary Artery Disease, Severe 56 73
Familial Dysbetalipoproteinemia 52 73
Hyperlipoproteinemia Type 3 52 58
Dysbetalipoproteinemia 52 58
Hyperlipidemia Type 3 52 58
Broad Beta Disease 52 73
Dysbetalipoproteinemia Due to Defect in Apolipoprotein E-D 56
Dysbetalipoproteinemia Due to Defect in Apolipoprotein E 73
Coronary Artery Disease, Severe, Susceptibility to 56
Familial Hypercholesterolaemia with Hyperlipaemia 12
Apolipoprotein E, Deficiency or Defect of 56
Deficiency or Defect of Apolipoprotein E 73
Familial Hyperlipoproteinemia Type Iii 74
Carbohydrate Induced Hyperlipemia 12
Familial Dyslipidemia Type 3 58
Remnant Hyperlipoproteinemia 58
Coronary Arteriosclerosis 71
Remnant Removal Disease 52
Coronary Heart Disease 71
Remnant Hyperlipidemia 12
Hyperlipoproteinemia 3 73
Broad-Beta Disease 58
Hlp Type 3 58
Hlpp3 73
Cad 73

Characteristics:

Orphanet epidemiological data:

58
dysbetalipoproteinemia
Inheritance: Autosomal dominant,Multigenic/multifactorial; Prevalence: 1-5/10000 (Worldwide); Age of onset: All ages; Age of death: normal life expectancy;

Classifications:

Orphanet: 58  
Inborn errors of metabolism
Rare endocrine diseases


External Ids:

Disease Ontology 12 DOID:3145
OMIM 56 617347
NCIt 49 C34710
SNOMED-CT 67 42569002
MESH via Orphanet 44 D006952
ICD10 via Orphanet 33 E78.2
UMLS via Orphanet 72 C0020479
Orphanet 58 ORPHA412
MedGen 41 C0020479
UMLS 71 C0010054 C0010068 C0020479 more

Summaries for Hyperlipoproteinemia, Type Iii

NIH Rare Diseases : 52 Hyperlipidemia type 3 is an inherited condition that disrupts the normal breakdown of fats (lipids) in the body, causing a large amount of certain fatty materials to build up in the body. Some individuals never have symptoms of this condition. Symptoms usually do not appear unless a second genetic or environmental factor adds to increased lipid levels. Symptoms may include: yellowish lipid-filled bumps on the skin (xanthomas), inflammation of the pancreas (pancreatitis), and a buildup of fat in the blood vessels (atherosclerosis). Hyperlipidemia type 3 may lead to the development of cardiovascular disease . This condition is caused by mutations in the APOE gene . The inheritance of this condition is considered to be complicated, as having mutations in the APOE gene often does not lead to the development of symptoms without the influence of other factors. Most people with symptoms of hyperlipidemia type 3 have two mutations in the APOE gene, inherited in an autosomal recessive manner. Treatment often includes management of diet, exercise, and use of lipid-lowering medications.

MalaCards based summary : Hyperlipoproteinemia, Type Iii, also known as coronary artery disease, is related to hypercholesterolemia, familial, 2 and hypoalphalipoproteinemia, and has symptoms including tremor, angina pectoris and edema. An important gene associated with Hyperlipoproteinemia, Type Iii is APOE (Apolipoprotein E), and among its related pathways/superpathways are cGMP-PKG signaling pathway and Wnt signaling pathway. The drugs Ethinyl Estradiol and Sulfasalazine have been mentioned in the context of this disorder. Affiliated tissues include heart, endothelial and testes, and related phenotypes are hypertriglyceridemia and increased ldl cholesterol concentration

Disease Ontology : 12 A familial hyperlipidemia that has material basis in by homozygous, compound heterozygous, or heterozygous mutation in the APOE gene on chromosome 19q13.

OMIM : 56 Hyperlipoproteinemia type III, also called dysbetalipoproteinemia, is characterized by hyperlipidemia due to accumulation of remnants of the triglyceride (TG)-rich lipoproteins (TGRL), very low density lipoproteins (VLDL), and chylomicrons (CM), in response to dysfunctional genetic variants of apolipoprotein E or absence of apoE (summary by Blum, 2016). (617347)

MedlinePlus : 42 Coronary artery disease (CAD) is the most common type of heart disease. It is the leading cause of death in the United States in both men and women. CAD happens when the arteries that supply blood to heart muscle become hardened and narrowed. This is due to the buildup of cholesterol and other material, called plaque, on their inner walls. This buildup is called atherosclerosis. As it grows, less blood can flow through the arteries. As a result, the heart muscle can't get the blood or oxygen it needs. This can lead to chest pain (angina) or a heart attack. Most heart attacks happen when a blood clot suddenly cuts off the hearts' blood supply, causing permanent heart damage. Over time, CAD can also weaken the heart muscle and contribute to heart failure and arrhythmias. Heart failure means the heart can't pump blood well to the rest of the body. Arrhythmias are changes in the normal beating rhythm of the heart. NIH: National Heart, Lung, and Blood Institute

KEGG : 36 Coronary artery disease (CAD) is one of the leading causes of death globally. CAD is coupled to a pathogenic process in which lipids and lipoproteins accumulate in the subendothelial intimal layer of the vessel wall. A variety of environmental and genetic risk factors are associated with CAD, including hypercholesterolemia, hypertension, obesity, diabetes, and a family history of early CAD. It has been reported that an autosomal dominant form of CAD is caused by the mutation in transcription factor MEF2A. A missense mutation in LRP6, which encodes a co-receptor in the Wnt signaling pathway, has also been identified.

UniProtKB/Swiss-Prot : 73 Coronary artery disease: A common heart disease characterized by reduced or absent blood flow in one or more of the arteries that encircle and supply the heart. Its most important complication is acute myocardial infarction.
Hyperlipoproteinemia 3: A disorder characterized by the accumulation of intermediate-density lipoprotein particles (IDL or broad-beta-lipoprotein) rich in cholesterol. Clinical features include xanthomas, yellowish lipid deposits in the palmar crease, or less specific on tendons and on elbows. The disorder rarely manifests before the third decade in men. In women, it is usually expressed only after the menopause.

PubMed Health : 62 About coronary artery disease: Coronary artery disease (CAD, also called coronary heart disease, or CHD) is caused by the narrowing of the large blood vessels that supply the heart with oxygen. These are called coronary arteries. Arteries that have become extremely narrow can cause shortness of breath and chest pain during physical activity. If a coronary artery suddenly becomes completely blocked, it can result in a heart attack. CAD can also lead to other health problems like heart failure or heart rhythm problems. Various treatments can be used to reduce the symptoms and the risk of complications.

Wikipedia : 74 Familial dysbetalipoproteinemia or type III hyperlipoproteinemia is a condition characterized by... more...

Related Diseases for Hyperlipoproteinemia, Type Iii

Diseases in the Hyperlipoproteinemia, Type Iii family:

Hyperlipoproteinemia, Type Iv Hyperlipoproteinemia, Type V
Hyperlipoproteinemia, Type I Hyperlipoproteinemia, Type Id

Diseases related to Hyperlipoproteinemia, Type Iii via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 882)
# Related Disease Score Top Affiliating Genes
1 hypercholesterolemia, familial, 2 32.4 LDLR APOE APOB
2 hypoalphalipoproteinemia 32.3 LIPC APOA1
3 arteriosclerosis 31.5 LPA LDLR APOE APOB APOA1
4 hyperlipoproteinemia, type v 31.0 LPL APOE APOB APOA5 APOA1
5 coronary artery anomaly 30.9 LPA APOB APOA1
6 acute myocardial infarction 30.8 LPA APOB APOA1
7 hyperlipoproteinemia, type iv 30.8 LPL LPA APOE APOB APOA5 APOA1
8 carotid stenosis 30.6 LPA APOE
9 silent myocardial infarction 30.5 LPA APOB
10 tangier disease 30.4 LPL LPA CETP APOE APOB APOA1
11 glucose intolerance 30.3 LPL APOB APOA1
12 stroke, ischemic 30.2 LPA LDLR APOE APOB
13 angina pectoris 30.2 LPA APOA1
14 peripheral vascular disease 30.2 LPA CETP APOB APOA1
15 carotid artery disease 30.2 LPA APOE APOB APOA1
16 platelet glycoprotein iv deficiency 30.1 APOE APOB
17 peripheral artery disease 29.9 APOE APOB APOA1
18 amyloidosis 29.9 LPA APOE APOA1
19 defective apolipoprotein b-100 29.9 LDLR APOE APOB
20 intermediate coronary syndrome 29.8 LPA APOB APOA1
21 arteries, anomalies of 29.8 LPA CETP APOE APOB APOA1
22 hyperalphalipoproteinemia 1 29.8 LPL LIPC LDLR CETP APOE APOB
23 familial combined hyperlipoproteinemia 29.8 LPL APOB APOA1
24 cerebral atherosclerosis 29.8 LPA APOE APOA1
25 generalized atherosclerosis 29.7 LPA APOE APOB
26 acquired immunodeficiency syndrome 29.7 APOE APOB APOA1
27 osteoporosis 29.5 LPA LDLR APOE APOB
28 macular degeneration, age-related, 1 29.3 LIPC CETP APOE APOB
29 sitosterolemia 29.3 APOB APOA1
30 diabetes mellitus, insulin-dependent 29.2 LPA CETP APOB APOA1
31 arcus corneae 29.2 LPA LDLR APOB APOA1
32 overnutrition 29.2 LPL APOE APOB APOA1
33 non-alcoholic fatty liver disease 29.2 LPL APOB APOA1
34 hepatic lipase deficiency 29.1 LPL LIPC APOE APOA1
35 xanthomatosis 29.0 LPL LPA LDLR APOE APOB
36 homozygous familial hypercholesterolemia 29.0 LIPC LDLR APOE APOB APOA1
37 coronary stenosis 28.9 LPL CETP APOE APOB APOA1
38 gallbladder disease 28.8 CETP APOE APOB APOA1
39 cardiovascular system disease 28.7 LPL LPA LIPC LDLR CETP APOE
40 aortic atherosclerosis 28.6 LPL LPA LIPC LDLR CETP APOE
41 alzheimer disease 28.5 LPL LPA LDLR CETP APOE APOB
42 kidney disease 28.5 LPA CETP APOE APOB APOA1
43 hypertension, essential 28.5 LPL LPA LDLR CETP APOE APOB
44 cerebrovascular disease 28.2 LPL LPA LDLR APOE APOB APOA1
45 hypolipoproteinemia 28.0 LPL LPA CETP APOE APOB APOA1
46 diabetes mellitus 27.9 LPL LPA LIPC CETP APOE APOB
47 hypothyroidism 27.7 LPL LPA LIPC LDLR CETP APOE
48 abetalipoproteinemia 27.7 LPL LPA LDLR CETP APOE APOB
49 hypertriglyceridemia, familial 27.5 LPL LIPC CETP APOE APOB APOA5
50 chronic kidney disease 27.4 LPL LPA LIPC CETP APOE APOB

Graphical network of the top 20 diseases related to Hyperlipoproteinemia, Type Iii:



Diseases related to Hyperlipoproteinemia, Type Iii

Symptoms & Phenotypes for Hyperlipoproteinemia, Type Iii

Human phenotypes related to Hyperlipoproteinemia, Type Iii:

58 31 (show all 26)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 hypertriglyceridemia 58 31 hallmark (90%) Very frequent (99-80%) HP:0002155
2 increased ldl cholesterol concentration 58 31 hallmark (90%) Very frequent (99-80%) HP:0003141
3 hypercholesterolemia 58 31 hallmark (90%) Very frequent (99-80%) HP:0003124
4 decreased hdl cholesterol concentration 58 31 hallmark (90%) Very frequent (99-80%) HP:0003233
5 obesity 58 31 frequent (33%) Frequent (79-30%) HP:0001513
6 diabetes mellitus 58 31 frequent (33%) Frequent (79-30%) HP:0000819
7 hepatomegaly 58 31 frequent (33%) Frequent (79-30%) HP:0002240
8 hepatic steatosis 58 31 frequent (33%) Frequent (79-30%) HP:0001397
9 corneal arcus 58 31 frequent (33%) Frequent (79-30%) HP:0001084
10 xanthelasma 58 31 frequent (33%) Frequent (79-30%) HP:0001114
11 tendon xanthomatosis 58 31 frequent (33%) Frequent (79-30%) HP:0010874
12 type iv atherosclerotic lesion 31 frequent (33%) HP:0002635
13 hypothyroidism 58 31 occasional (7.5%) Occasional (29-5%) HP:0000821
14 angina pectoris 58 31 occasional (7.5%) Occasional (29-5%) HP:0001681
15 peripheral arterial stenosis 58 31 occasional (7.5%) Occasional (29-5%) HP:0004950
16 gout 58 31 occasional (7.5%) Occasional (29-5%) HP:0001997
17 accelerated atherosclerosis 58 31 occasional (7.5%) Occasional (29-5%) HP:0004943
18 renal steatosis 58 31 occasional (7.5%) Occasional (29-5%) HP:0000799
19 acute pancreatitis 58 31 occasional (7.5%) Occasional (29-5%) HP:0001735
20 premature coronary artery atherosclerosis 31 occasional (7.5%) HP:0005181
21 aortic atherosclerotic lesion 31 occasional (7.5%) HP:0012397
22 abnormality of the skin 58 Very frequent (99-80%)
23 premature coronary artery disease 58 Occasional (29-5%)
24 atheromatosis 58 Frequent (79-30%)
25 premature peripheral vascular disease 58 Occasional (29-5%)
26 aortic atherosclerosis 58 Occasional (29-5%)

Clinical features from OMIM:

617347

UMLS symptoms related to Hyperlipoproteinemia, Type Iii:


tremor, angina pectoris, edema, chest pain, equilibration disorder, substernal pain

GenomeRNAi Phenotypes related to Hyperlipoproteinemia, Type Iii according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased free cholesterol GR00340-A-2 9.61 APOA1 APOA5 APOB APOE CETP LDLR
2 Increased LDL uptake GR00340-A-1 8.92 APOA1 APOE LDLR LPL

MGI Mouse Phenotypes related to Hyperlipoproteinemia, Type Iii:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 liver/biliary system MP:0005370 9.02 APOA1 APOB APOE LDLR LPL

Drugs & Therapeutics for Hyperlipoproteinemia, Type Iii

PubMed Health treatment related to Hyperlipoproteinemia, Type Iii: 62

The main goals of treatment for CAD are to relieve symptoms and prevent complications. Medication can reduce the symptoms and restrictions in everyday life caused by stable angina . Beta blockers , calcium channel blockers and nitrates are used for this purpose. If that doesn't help, doctors often try to widen the narrowed coronary artery with a procedure using a cardiac catheter . If the arteries are severely narrowed, or if several blood vessels are affected, bypass surgery may be considered. This involves taking a blood vessel from elsewhere in the body and using it to redirect blood around the blocked coronary artery (bypassing it). There are things you can do on your own to help prevent complications like a heart attack or heart failure : eating a healthy diet and getting enough exercise are two examples. If you smoke, you could try to give it up. Also, there are a number of different medications that can prevent complications and increase life expectancy. These include the following: Low doses of acetylsalicylic acid (the drug in medicines like "Aspirin ") to prevent blood clots Statins to protect the blood vessels Beta blockers to reduce the strain on the heart (especially in people with heart failure or high blood pressure )

Drugs for Hyperlipoproteinemia, Type Iii (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 916)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
2
Sulfasalazine Approved Phase 4 599-79-1 5353980 5359476
3
Hydromorphone Approved, Illicit Phase 4 466-99-9 5284570
4
Coal tar Approved Phase 4 8007-45-2
5
Nicardipine Approved, Investigational Phase 4 55985-32-5 4474
6
Fenoldopam Approved Phase 4 67227-56-9, 67227-57-0 3341
7
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
8
Cyproterone Acetate Approved, Investigational Phase 4 427-51-0
9
Udenafil Approved, Investigational Phase 4 268203-93-6 6918523
10
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
11
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
12
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
13
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
14 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
15
Eplerenone Approved Phase 4 107724-20-9 150310 443872
16
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
17
Ticlopidine Approved Phase 4 55142-85-3 5472
18
Glipizide Approved, Investigational Phase 4 29094-61-9 3478
19
Probucol Approved, Investigational Phase 4 23288-49-5 4912
20
Nitroglycerin Approved, Investigational Phase 4 55-63-0 4510
21
Digoxin Approved Phase 4 20830-75-5 30322 2724385
22
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
23
Lovastatin Approved, Investigational Phase 4 75330-75-5 53232
24
Atropine Approved, Vet_approved Phase 4 5908-99-6, 51-55-8 174174
25
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
26
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
27
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
28
Cosyntropin Approved Phase 4 16960-16-0 16129617
29
Etomidate Approved Phase 4 33125-97-2 36339 667484
30
Histamine Approved, Investigational Phase 4 51-45-6 774
31
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
32
Polyestradiol phosphate Approved Phase 4 28014-46-2
33
Bezafibrate Approved, Investigational Phase 4 41859-67-0 39042
34
Progesterone Approved, Vet_approved Phase 4 57-83-0 5994
35
Salicylic acid Approved, Investigational, Vet_approved Phase 4 69-72-7 338
36
Famotidine Approved Phase 4 76824-35-6 3325
37
Norepinephrine Approved Phase 4 51-41-2 439260
38
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
39
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
40
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
41
Vildagliptin Approved, Investigational Phase 4 274901-16-5 6918537
42
Remifentanil Approved Phase 4 132875-61-7 60815
43
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
44
Saxagliptin Approved Phase 4 361442-04-8 11243969
45
Vorapaxar Approved Phase 4 618385-01-6
46
Repaglinide Approved, Investigational Phase 4 135062-02-1 65981
47
Citalopram Approved Phase 4 59729-33-8 2771
48
Magnesium citrate Approved Phase 4 3344-18-1
49
Nifedipine Approved Phase 4 21829-25-4 4485
50
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139

Interventional clinical trials:

(show top 50) (show all 6129)
# Name Status NCT ID Phase Drugs
1 Randomized Placebo-controlled Crossover Trial of Endothelial Function Improvement in Subjects With History of Premature Coronary Artery Disease Unknown status NCT00917527 Phase 4 Atorvastatin
2 The Impact of Compound Danshen Dropping Pill for Coronary Heart Disease With Hypertension Patient Heart and Artery Structure and Function Unknown status NCT01825759 Phase 4 danshen dripping pill
3 Hydroxychloroquine Assessment of Management Study in Coronary Artery Disease After Angiography. Unknown status NCT02874287 Phase 4 Hydroxychloroquine Sulfate Tablets;Placebo Tablets
4 Rosuvastatin Effect on Reducing Coronary Atherosclerosis Plaques Volume Evaluated by Multi-slice Spiral CT in Patients With Stable Coronary Heart Disease and Hyperlipidemia Unknown status NCT01382277 Phase 4 Rosuvastatin
5 Ischemia In Hemodialysed Patients And Outcome: Ivabradine Versus Carvedilol. A Randomized, Double Blind Study Unknown status NCT01425164 Phase 4 Ivabradine;Carvedilol
6 The Efficacy of Lescol XL(Fluvastatin Extended Release 80 mg) on Atherosclerosis Progression in Patients With Newly Diagnosed Coronary Heart Disease Unknown status NCT01681199 Phase 4 Fluvastatin extended release tablet
7 A Randomised, Placebo Controlled, Double Blind, Cross-over, Single Center Clinical Study to Investigate the Effect of Heart Rate Reduction With Ivabradine on Vascular Elastic Properties and Endothelial Function in Patients With Stable Coronary Heart Disease Unknown status NCT01768585 Phase 4 Ivabradine;Placebo
8 Comparison of Diabetes Mellitus and Non-diabetes Mellitus Patients for Surface Coverage After Two Types of Drug-eluting Stent Implantation (A Pilot Study) Unknown status NCT01021930 Phase 4
9 The Effect of Tongguan Capsule for MicroRNA Profiles Between Qi-Stagnation and Qi-Deficiency in Coronary Heart Disease Patients With Blood Stasis Syndrome Undergoing Percutaneous Coronary Intervention Unknown status NCT02850627 Phase 4 Tongguan capsule;placebo capsule
10 Prospective, Randomized Study of the Platelet Inhibitory Efficacy of Ticagrelor Versus Prasugrel in Clopidogrel Low Responders After Percutaneous Coronary Intervention Unknown status NCT01456364 Phase 4 Ticagrelor;Prasugrel
11 Different Dosage of Domestic and Imported Clopidogrel on the Platelet Inhibition Ratio in Patients Undergoing PCI Unknown status NCT03006835 Phase 4 Clopidogrel
12 RANDOMIZED TRIAL OF ZOTAROLIMUS- AND EVEROLIMUS-ELUTING STENTS REGARDING STENT COVERAGE ASSESSED BY OCT Unknown status NCT01230723 Phase 4
13 Bivalirudin in Stable Ischemic Heart Disease Patients Undergoing PCI Unknown status NCT02787317 Phase 4 bivalirudin;Heparin
14 The Effects of Pravastatin and Rosuvastatin on the Tissue Characteristics and Morphology of Coronary Plaques in Patients With Stable Angina Pectoris Unknown status NCT01325818 Phase 4 pravastatin, rosuvastatin
15 Impact of Stent Platform on Shear Stress Distribution and Subsequent Vessel Healing After Drug-eluting Stent Implantation (SHEAR DES) Unknown status NCT01942044 Phase 4
16 Randomized Comparison of Biolimus-Eluting and Everolimus-Eluting Stents With Optical Coherence Tomography Guided Stent Implantation in ST Elevation Myocardial Infarction.A 9-Month Angiographic and Optical Coherence Tomography Follow-up. Unknown status NCT00888758 Phase 4
17 Prospective, Randomized Trial of Limus-Eluting Stents With Biodegradable or Permanent Polymer Coatings Unknown status NCT01068106 Phase 4
18 Pilop Trial of OCT-determined Coverage of Permanent or Polymer-free Sirolimus Eluting Stent at Long Term Unknown status NCT01260558 Phase 4
19 Comparison of the Efficacy and Safety of New Platform Everolimus-eluting Coronary Stent System (Promus Element) With Zotarolimus-eluting Coronary Stent System (Endeavor Resolute) and Triple Anti-platelet Therapy With Double-dose Clopidogrel Anti-platelet Therapy in Patients With Coronary Heart Disease Unknown status NCT01267734 Phase 4 Triple anti-platelet therapy (TAT);Double-dose clopidogrel anti-platelet therapy (DDAT)
20 The Low HDL On Six Weeks Statin Therapy (LOW) Study Unknown status NCT00238004 Phase 4 Nicotinic acid
21 Comparison of Biolimus-eluting Biodegradable Polymer, Everolimus-eluting and Sirolimus-eluting Coronary Stents Unknown status NCT01268371 Phase 4
22 A Multi Center Registry to Evaluate Multiple Stenting Using by Everolimus-eluting Stents for Treatment of Long Coronary Artery Disease Unknown status NCT01147237 Phase 4
23 Clinical Evaluation of the Momo Cobalt-Chromium Coronary Stent System for the Treatment of Patients With Coronary Artery Disease Unknown status NCT01535625 Phase 4
24 Randomized Controlled Clinical Study to Compare the Efficacy and Safety of Different Dose of Tirofiban in Interventional Treatment of Complex Coronary Artery Disease Unknown status NCT02294994 Phase 4 tirofiban
25 Comparison of Efficacy and Safety of Ivabradine Versus Metoprolol for Controlling Heart Rate Prior to 640-Slice Computed Tomographic Angiography in Elective Patients Unknown status NCT01755663 Phase 4 Ivabradine and Metoprolol
26 Simultaneous Acquisition of Intravascular Ultrasound and Near Infrared Spectroscopy Data in the Coronary Artery Study Unknown status NCT02154295 Phase 4
27 A Multicenter, Open Labeled, Cross-Over Designed Prospective Study Evaluating the Effects of Lipid Lowering Treatment on Steroid Synthesis Unknown status NCT00433823 Phase 4 Atorvastatin, Ezetimibe
28 Effect of Early Administration of Intracoronary Nicorandil Via Thrombus Aspiration Catheter Device During Primary Percutaneous Coronary Intervention for the Patients of Acute ST Segment Elevation Myocardial Infarction Unknown status NCT02435797 Phase 4 Nicorandil;normal saline
29 Clinical Study of Combination Therapy for Angina of Coronary Heart Disease With Aspirin and Salvianolate Injection Based on Population Pharmacokinetics and Therapeutic Effect:A Randomized, Controlled Trial Unknown status NCT02694848 Phase 4 Salvianolate injection;Aspirin
30 Ranolazine, Ethnicity and the Metabolic Syndrome - REMS Study Unknown status NCT01304095 Phase 4 Ranolazine
31 The Effects of Omega 3 and Vitamin E Supplementation on the Serum Antioxidant Enzymes and Gene Expressions of PGC-1a, h TERT, FOXOs and SIRTs in CAD Patients Unknown status NCT02011906 Phase 4
32 Graft Patency After FFR-guided Versus Angio-guided CABG: a Prospective, Multicenter, Multinational, Randomized (1:1) Controlled Trial Unknown status NCT01810224 Phase 4
33 Epicardial Fat Evaluation to Predict Clinical Outcomes in Patients Affected by Coronary Artery Disease and Treated by Coronary Artery Bypass Grafting: Diabetic vs. Non Diabetic Patients, and Incretin Therapy Effect; The EPI.FAT.IN Study Unknown status NCT03360981 Phase 4 Incretins
34 Overcoming High On-Treatment Platelet Reactivity (HPR) During Prasugrel Therapy Unknown status NCT01869309 Phase 4 Prasugrel;Ticagrelor
35 Prospective Multicenter Registry of Hybrid Coronary Artery Revascularization Combined With Surgical Bypass and Percutaneous Coronary Intervention Using Everolimus Eluting Metallic Stents Unknown status NCT02894255 Phase 4
36 Low Dose Statins, Ezetimibe and Nutraceuticals in Coronary Artery Disease Patients Intolerant to High Intensity Statin Treatment (TArget ChOlesterol) Unknown status NCT03277079 Phase 4 statin + ezetimibe;statin + ezetimibe + Nutraceuticals
37 Effect of Preoperative Aspirin in Patients Undergoing Off-pump Coronary Artery Bypass Grafting: A Double-blind, Placebo-controlled, Randomized Trial Unknown status NCT03049085 Phase 4 Aspirin;vitamin C
38 Rosiglitazone Therapy In The Prevention Of Coronary Artery Disease In Patients With Impaired Glucose Tolerance Unknown status NCT00733174 Phase 4 Rosiglitazone;Placebo
39 A Randomized, Double-blind, Multi-centered, Placebo-controlled Trial to Examine Effects of Heart-protecting Musk Pill on Clinical Outcome in Patients With Chronic Stable Coronary Artery Disease Unknown status NCT01897805 Phase 4 Heart-protecting Musk Pill;Placebo
40 Study of Curative Effect Evaluation of Shexiang Baoxin Pill on Coronary Artery Disease Not Amenable to Revascularization on the Basis of Western Medicine Therapy Unknown status NCT03072121 Phase 4 Shexiang Baoxin pill;SBP placebo;Aspirin Enteric-coated Tablets;Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet;Atorvastatin Calcium;Isosorbide Mononitrate Tab 20 MG;Metoprolol Tartrate Tab 25 MG;Trimetazidine Dihydrochloride Tablets
41 Study of Curative Effect Evaluation of DanLou Tablet on Coronary Artery Disease Not Amenable to Revascularization on the Basis of Western Medicine Therapy Unknown status NCT03072082 Phase 4 Danlou Tablet;DanLou Tablet placebo;Aspirin Enteric-coated Tablets;Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet;Atorvastatin calcium;Isosorbide Mononitrate Tab 20 MG;Metoprolol Tartrate Tab 25 MG;Trimetazidine Dihydrochloride Tablets
42 Diagnostic Value of a Rapid Protocol Regadenoson Stress Cardiovascular Magnetic Resonance Scan for Detection of Coronary Artery Disease Unknown status NCT01446094 Phase 4 regadenoson
43 Studies of Application of Combined General Anesthesia and Bilateral Thoracic Paravertebral Block by Ropivacaine in Patients Undergoing Off-pump Coronary Artery Bridge Graft - a Random Double Blind Controlled Study Unknown status NCT02727712 Phase 4 Anesthesia drugs during the surgery
44 A Prospective Multicenter Trial Evaluating Helios Biodegradable Polymer Sirolimus-eluting Stent Safety and Effectiveness in Treatment of Coronary Artery Disease Unknown status NCT01880879 Phase 4
45 The Beneficial Role of Percutaneous Coronary Intervention Over Optimal Medical Therapy in Elderly Patients (Age > 75 Years Old) With Coronary Artery Disease: a Randomized Controlled Study Unknown status NCT01508663 Phase 4 ARB, CCB, ACE-inhibitor, statin, Nitrate, Antiplate etc.
46 Randomized Trial of the Association Between Low-Dose Statins and Nutraceuticals in High-intEnsity Statin-intoleRant patiENts With Very High Risk Coronary Artery diseasE Unknown status NCT02001883 Phase 4 Association low-dose statin and nutraceuticals
47 Phase 4 Study of Patients Receiving BNP or NTG (IV) During Angioplasty, Re-examined 24 Hours Later Using the Flow-mediated Brachial Artery Dilation Study, and Blood Assays for Pro BNP and ET1 Unknown status NCT00262574 Phase 4 Nesiritide,
48 Apposition Assessed Using Optical Coherence Tomography of Chromium Stents Eluting Everolimus From Cobalt Versus Platinum Alloy Platforms. Unknown status NCT01776567 Phase 4
49 A Comparative Evaluation of Efficacy and Safety in the 3-Months DAPT Group vs. the 6-Months DAPT Group of Patients Treated With the Coroflex ISAR Stent; A Prospective, Multicenter, Randomized, Open-Label Clinical Trial Unknown status NCT02609698 Phase 4 3 months DAPT;6 months DAPT
50 Comparison of the Pharmacodynamic Effects of RanOlazine Versus aMlodipine on Platelet Reactivity in Stable Patients With Coronary Artery Disease Treated With Dual ANtiplatelet Therapy - The ROMAN Randomized Study Unknown status NCT01490255 Phase 4 Ranolazine;Amlodipine

Search NIH Clinical Center for Hyperlipoproteinemia, Type Iii

Inferred drug relations via UMLS 71 / NDF-RT 50 :


atorvastatin
Atorvastatin calcium
cerivastatin
Cerivastatin sodium
Cholestyramine Resin
Clofibrate
colesevelam
Colesevelam hydrochloride
Colestipol
Colestipol Hydrochloride
Dextrothyroxine
Dextrothyroxine Sodium
eptifibatide
Fenofibrate
Fish Liver Oils
fluvastatin
Fluvastatin sodium
Gemfibrozil
Isosorbide
Isosorbide Dinitrate
Isosorbide Mononitrate
Lovastatin
Pravastatin
Pravastatin Sodium
Probucol
rosuvastatin
Simvastatin
Sulfinpyrazone
tirofiban
TIROFIBAN HYDROCHLORIDE

Cochrane evidence based reviews: hyperlipoproteinemia type iii

Genetic Tests for Hyperlipoproteinemia, Type Iii

Genetic tests related to Hyperlipoproteinemia, Type Iii:

# Genetic test Affiliating Genes
1 Familial Type 3 Hyperlipoproteinemia 29 APOE
2 Coronary Artery Disease 29

Anatomical Context for Hyperlipoproteinemia, Type Iii

MalaCards organs/tissues related to Hyperlipoproteinemia, Type Iii:

40
Heart, Endothelial, Testes, Kidney, Bone, Liver, Lung

Publications for Hyperlipoproteinemia, Type Iii

Articles related to Hyperlipoproteinemia, Type Iii:

(show top 50) (show all 30144)
# Title Authors PMID Year
1
Studies of familial type III hyperlipoproteinemia using as a genetic marker the apoE phenotype E2/2. 61 56 6
7175379 1982
2
Genetic heterogeneity in familial dysbetalipoproteinemia. The E2(lys146----gln) variant results in a dominant mode of inheritance. 56 6
2313204 1990
3
The molecular basis of a familial apoE deficiency. An acceptor splice site mutation in the third intron of the deficient apoE gene. 56 6
3029073 1987
4
Familial apolipoprotein E deficiency. 56 6
3771793 1986
5
Identification of a new structural variant of human apolipoprotein E, E2(Lys146 leads to Gln), in a type III hyperlipoproteinemic subject with the E3/2 phenotype. 56 6
6313758 1983
6
Type III hyperlipoproteinemia associated with apolipoprotein E deficiency. 56 6
6795720 1981
7
Polymorphisms in the apolipoprotein A5 (APOA5) gene and type III hyperlipidemia. 54 6
16143024 2005
8
Type III hyperlipoproteinemia and spontaneous atherosclerosis in mice resulting from gene replacement of mouse Apoe with human Apoe*2. 54 6
9649566 1998
9
Dominant expression of type III hyperlipoproteinemia. Pathophysiological insights derived from the structural and kinetic characteristics of ApoE-1 (Lys146-->Glu). 54 6
7635945 1995
10
Familial apolipoprotein E deficiency and type III hyperlipoproteinemia due to a premature stop codon in the apolipoprotein E gene. 54 6
1361196 1992
11
Apolipoprotein epsilon 4 and coronary artery disease. 61 56
1360057 1992
12
Apolipoprotein epsilon 4 and coronary artery disease. 61 56
1360061 1992
13
Apolipoprotein epsilon 4 and coronary artery disease. 61 56
1360062 1992
14
Severe type III hyperlipoproteinemia associated with unusual apolipoprotein E1 phenotype and epsilon 1/'null' genotype. 54 6
1360898 1992
15
The functional characteristics of a human apolipoprotein E variant (cysteine at residue 142) may explain its association with dominant expression of type III hyperlipoproteinemia. 54 6
1730728 1992
16
Apolipoprotein E3-Leiden. A new variant of human apolipoprotein E associated with familial type III hyperlipoproteinemia. 61 6
3721502 1986
17
Type III Hyperlipoproteinemia: Still Worth Considering? 56
27481046 2016
18
Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. 6
22962670 2012
19
Apolipoprotein E genotypes are associated with lipid-lowering responses to statin treatment in diabetes: a Go-DARTS study. 56
18334912 2008
20
Polymorphisms associated with cholesterol and risk of cardiovascular events. 56
18354102 2008
21
Subsets of SNPs define rare genotype classes that predict ischemic heart disease. 56
17006673 2007
22
Influence of apolipoprotein E epsilon4 genotype on brain tissue integrity in relapsing-remitting multiple sclerosis. 6
15096402 2004
23
Unusual xanthomas in a young patient with heterozygous familial hypercholesterolemia and type III hyperlipoproteinemia. 56
8911609 1996
24
Characterization of a novel variant of apolipoprotein E, E2 Fukuoka (Arg-224 --> Gln) in a hyperlipidemic patient with xanthomatosis. 6
8664327 1996
25
Genetic associations with human longevity at the APOE and ACE loci. 56
8136829 1994
26
Characterization of five new mutants in the carboxyl-terminal domain of human apolipoprotein E: no cosegregation with severe hyperlipidemia. 6
8488843 1993
27
Apolipoprotein epsilon 4 homozygosity in young men with coronary heart disease. 56
1357300 1992
28
Apolipoprotein E1 Lys-146----Glu with type III hyperlipoproteinemia. 6
1356443 1992
29
Apolipoprotein E-4Philadelphia (Glu13----Lys,Arg145----Cys). Homozygosity for two rare point mutations in the apolipoprotein E gene combined with severe type III hyperlipoproteinemia. 6
1674745 1991
30
Identification and characterization of a new variant of apolipoprotein E (apo E-Kochi). 6
2101409 1990
31
Apolipoprotein E3-Leiden contains a seven-amino acid insertion that is a tandem repeat of residues 121-127. 6
2556398 1989
32
Increased frequencies of apolipoprotein epsilon 2 and epsilon 4 alleles in patients with ischemic heart disease. 56
2791332 1989
33
Type III hyperlipoproteinemia associated with apolipoprotein E phenotype E3/3. Structure and genetics of an apolipoprotein E3 variant. 6
2539388 1989
34
Genotyping and sequence analysis of apolipoprotein E isoforms. 6
3243553 1988
35
Simultaneous effects of the apolipoprotein E polymorphism on apolipoprotein E, apolipoprotein B, and cholesterol metabolism. 56
3337104 1988
36
Familial dysbetalipoproteinemic subjects with the E3/E2 phenotype exhibit an E2 isoform with only one cysteine residue. 56
3690877 1987
37
Apolipoprotein E2-Christchurch (136 Arg----Ser). New variant of human apolipoprotein E in a patient with type III hyperlipoproteinemia. 6
3038959 1987
38
ApoE deficiency: markedly decreased levels of cellular ApoE mRNA. 56
3004475 1986
39
Isolation and characterisation of a variant allele of the gene for human apolipoprotein E. 6
2992507 1985
40
Lipoprotein receptors in the liver. Control signals for plasma cholesterol traffic. 56
6309907 1983
41
Cholesteryl ester accumulation in mouse peritoneal macrophages induced by beta-migrating very low density lipoproteins from patients with atypical dysbetalipoproteinemia. 56
6309903 1983
42
Atypical familial dysbetalipoproteinemia associated with apolipoprotein phenotype E3/3. 6
6860421 1983
43
Identical structural and receptor binding defects in apolipoprotein E2 in hypo-, normo-, and hypercholesterolemic dysbetalipoproteinemia. 6
6300187 1983
44
Structural basis for receptor binding heterogeneity of apolipoprotein E from type III hyperlipoproteinemic subjects. 56
6289314 1982
45
Familial dysbetalipoproteinemia. Abnormal binding of mutant apoprotein E to low density lipoprotein receptors of human fibroblasts and membranes from liver and adrenal of rats, rabbits, and cows. 56
6270194 1981
46
Regulation of plasma cholesterol by lipoprotein receptors. 56
6261329 1981
47
Type III hyperlipoproteinemia: defective metabolism of an abnormal apolipoprotein E. 56
7455696 1981
48
Genetic transmission of isoapolipoprotein E phenotypes in a large kindred: relationship to dysbetalipoproteinemia and hyperlipidemia. 56
7464557 1981
49
Polymorphism of apolipoprotein E. III. Effect of a single polymorphic gene locus on plasma lipid levels in man. 56
759055 1979
50
Type III hyperlipoproteinemia: diagnosis in whole plasma by apolipoprotein-E immunoassay. 56
200160 1977

Variations for Hyperlipoproteinemia, Type Iii

ClinVar genetic disease variations for Hyperlipoproteinemia, Type Iii:

6 (show all 16) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 APOE NM_000041.4(APOE):c.388T>C (p.Cys130Arg)SNV Likely pathogenic,risk factor 17864 rs429358 19:45411941-45411941 19:44908684-44908684
2 APOE NM_000041.4(APOE):c.488G>A (p.Arg163His)SNV Pathogenic 17865 rs121918397 19:45412041-45412041 19:44908784-44908784
3 APOE NM_000041.4(APOE):c.237-2A>GSNV Pathogenic 17852 rs397514253 19:45411788-45411788 19:44908531-44908531
4 APOE NM_000041.4(APOE):c.415_435dup (p.Glu139_Gly145dup)duplication Pathogenic 17853 rs397514254 19:45411963-45411964 19:44908706-44908707
5 APOE NM_000041.4(APOE):c.490A>G (p.Lys164Glu)SNV Pathogenic 17857 rs121918394 19:45412043-45412043 19:44908786-44908786
6 APOE NM_000041.4(APOE):c.490A>C (p.Lys164Gln)SNV Pathogenic 17858 rs121918394 19:45412043-45412043 19:44908786-44908786
7 APOE NM_000041.4(APOE):c.91G>A (p.Glu31Lys)SNV Pathogenic 440842 rs201672011 19:45411064-45411064 19:44907807-44907807
8 APOE APOE, 1-BP DEL, 2919Gdeletion Pathogenic 17861
9 APOE NM_000041.4(APOE):c.683G>A (p.Trp228Ter)SNV Pathogenic 17862 rs121918396 19:45412236-45412236 19:44908979-44908979
10 APOE NM_000041.4(APOE):c.460C>A (p.Arg154Ser)SNV Pathogenic 17850 rs121918393 19:45412013-45412013 19:44908756-44908756
11 APOE NM_000041.2(APOE):c.526C>T (p.Arg176Cys)SNV drug response 17848 rs7412 19:45412079-45412079 19:44908822-44908822
12 APOE NM_000041.4(APOE):c.487C>T (p.Arg163Cys)SNV Benign 17851 rs769455 19:45412040-45412040 19:44908783-44908783
13 APOE NM_000041.4(APOE):c.478C>T (p.Arg160Cys)SNV no interpretation for the single variant 487346 rs387906567 19:45412031-45412031 19:44908774-44908774
14 APOE NM_000041.2(APOE):c.725G>A (p.Arg242Gln)SNV no interpretation for the single variant 478870 rs267606663 19:45412278-45412278 19:44909021-44909021
15 APOE NM_000041.4(APOE):c.761T>A (p.Val254Glu)SNV no interpretation for the single variant 478872 rs199768005 19:45412314-45412314 19:44909057-44909057
16 APOE NM_000041.4(APOE):c.805C>G (p.Arg269Gly)SNV no interpretation for the single variant 478884 rs267606661 19:45412358-45412358 19:44909101-44909101

UniProtKB/Swiss-Prot genetic disease variations for Hyperlipoproteinemia, Type Iii:

73
# Symbol AA change Variation ID SNP ID
1 APOE p.Glu31Lys VAR_000646 rs201672011
2 APOE p.Cys130Arg VAR_000652 rs429358
3 APOE p.Arg154Ser VAR_000656 rs121918393
4 APOE p.Arg154Cys VAR_000657 rs121918393
5 APOE p.Arg160Cys VAR_000658 rs387906567
6 APOE p.Arg163Cys VAR_000659 rs769455
7 APOE p.Lys164Gln VAR_000661 rs121918394
8 APOE p.Lys164Glu VAR_000662 rs121918394
9 APOE p.Arg176Cys VAR_000664 rs7412

Expression for Hyperlipoproteinemia, Type Iii

Search GEO for disease gene expression data for Hyperlipoproteinemia, Type Iii.

Pathways for Hyperlipoproteinemia, Type Iii

Pathways related to Hyperlipoproteinemia, Type Iii according to KEGG:

36
# Name Kegg Source Accession
1 cGMP-PKG signaling pathway hsa04022
2 Wnt signaling pathway hsa04310

Pathways related to Hyperlipoproteinemia, Type Iii according to GeneCards Suite gene sharing:

(show all 15)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.63 LPL LPA LIPC LDLR CETP APOE
2
Show member pathways
12.26 LPL LDLR APOE APOB APOA1
3
Show member pathways
12 LDLR APOE APOB APOA1
4
Show member pathways
11.88 LPL LDLR APOE APOB APOA1
5
Show member pathways
11.81 LPL LPA LIPC LDLR CETP APOE
6 11.74 APOE APOA5 APOA1
7
Show member pathways
11.68 LPL LPA LIPC LDLR CETP APOE
8
Show member pathways
11.63 APOE APOB APOA1
9 11.46 LPL APOA5 APOA1
10
Show member pathways
11.27 LPL LIPC
11 11.22 LPA APOB
12
Show member pathways
11.17 APOB APOA1
13 11.02 LDLR APOE
14 10.91 APOA5 APOA1
15 10.86 APOB APOA1

GO Terms for Hyperlipoproteinemia, Type Iii

Cellular components related to Hyperlipoproteinemia, Type Iii according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 10.06 LPL LPA LIPC CETP APOE APOB
2 extracellular space GO:0005615 10.04 LPL LIPC CETP APOE APOB APOA5
3 endoplasmic reticulum lumen GO:0005788 9.83 LIPC APOE APOB APOA5 APOA1
4 early endosome GO:0005769 9.77 LDLR APOE APOB APOA5 APOA1
5 clathrin-coated endocytic vesicle membrane GO:0030669 9.65 LDLR APOE APOB
6 very-low-density lipoprotein particle GO:0034361 9.65 LPL APOE APOB APOA5 APOA1
7 endocytic vesicle lumen GO:0071682 9.58 APOE APOB APOA1
8 low-density lipoprotein particle GO:0034362 9.55 LDLR APOE APOB APOA5 APOA1
9 extracellular vesicle GO:1903561 9.52 APOE APOA1
10 discoidal high-density lipoprotein particle GO:0034365 9.51 APOE APOA1
11 intermediate-density lipoprotein particle GO:0034363 9.5 APOE APOB APOA1
12 chylomicron GO:0042627 9.35 LPL APOE APOB APOA5 APOA1
13 high-density lipoprotein particle GO:0034364 9.1 LIPC CETP APOE APOB APOA5 APOA1

Biological processes related to Hyperlipoproteinemia, Type Iii according to GeneCards Suite gene sharing:

(show top 50) (show all 55)
# Name GO ID Score Top Affiliating Genes
1 lipid metabolic process GO:0006629 10.06 LPL LPA LIPC LDLR CETP APOE
2 post-translational protein modification GO:0043687 9.98 APOE APOB APOA5 APOA1
3 cellular protein metabolic process GO:0044267 9.96 APOE APOB APOA5 APOA1
4 steroid metabolic process GO:0008202 9.96 LDLR CETP APOE APOB APOA1
5 receptor-mediated endocytosis GO:0006898 9.94 LDLR APOE APOB APOA1
6 cholesterol metabolic process GO:0008203 9.91 LIPC LDLR CETP APOE APOB APOA1
7 retinoid metabolic process GO:0001523 9.9 LPL APOE APOB APOA1
8 lipid catabolic process GO:0016042 9.87 LPL LIPC APOB
9 triglyceride metabolic process GO:0006641 9.87 LPL CETP APOE APOA5
10 lipid transport GO:0006869 9.87 LPA LDLR CETP APOE APOB APOA5
11 cholesterol efflux GO:0033344 9.85 APOE APOB APOA5 APOA1
12 triglyceride catabolic process GO:0019433 9.84 LPL LIPC APOB APOA5
13 reverse cholesterol transport GO:0043691 9.83 LIPC CETP APOE APOA1
14 phospholipid transport GO:0015914 9.82 LDLR CETP APOA1
15 artery morphogenesis GO:0048844 9.81 LDLR APOE APOB
16 high-density lipoprotein particle remodeling GO:0034375 9.81 LIPC CETP APOE APOA1
17 phosphatidylcholine metabolic process GO:0046470 9.8 CETP APOA5 APOA1
18 high-density lipoprotein particle assembly GO:0034380 9.8 APOE APOA5 APOA1
19 chylomicron remnant clearance GO:0034382 9.8 LIPC LDLR APOE APOB
20 lipoprotein metabolic process GO:0042157 9.8 LDLR APOE APOB APOA5 APOA1
21 phospholipid efflux GO:0033700 9.79 APOE APOA5 APOA1
22 high-density lipoprotein particle clearance GO:0034384 9.79 LDLR APOE APOA1
23 chylomicron assembly GO:0034378 9.78 APOE APOB APOA1
24 chylomicron remodeling GO:0034371 9.78 LPL APOE APOB APOA1
25 positive regulation of cholesterol esterification GO:0010873 9.77 APOE APOA5 APOA1
26 cholesterol transport GO:0030301 9.77 LIPC LDLR CETP APOB APOA1
27 lipoprotein biosynthetic process GO:0042158 9.76 APOE APOB APOA1
28 lipoprotein catabolic process GO:0042159 9.75 LDLR APOE APOB
29 lipid homeostasis GO:0055088 9.72 CETP APOE
30 cholesterol biosynthetic process GO:0006695 9.72 APOA5 APOA1
31 long-term memory GO:0007616 9.71 LDLR APOE
32 cellular response to fatty acid GO:0071398 9.71 LPL LDLR
33 low-density lipoprotein particle clearance GO:0034383 9.71 LDLR APOB
34 positive regulation of macrophage derived foam cell differentiation GO:0010744 9.71 LPL APOB
35 positive regulation of cholesterol efflux GO:0010875 9.71